Biogen Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD 2.58 B

Biogen Inc. Operating Cash Flow is USD 2.58 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 56.93% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Biogen Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 1.65 B, a -1.95% change year over year.
  • Biogen Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 1.68 B, a -44.68% change year over year.
  • Biogen Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 3.03 B, a -14.12% change year over year.
  • Biogen Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 3.53 B, a -50.17% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities